Why is "Cholesterol 24-hydroxylase" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-28 01:11:52
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Cholesterol_24-hydroxylase entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-28 and was most recently seen on 2026-07-28.
Wikipedia Overview
Cholesterol 24-hydroxylase, also commonly known as cholesterol 24S-hydroxylase, cholesterol 24-monooxygenase, CYP46, or CYP46A1, is an enzyme that catalyzes the conversion of cholesterol to 24S-hydroxycholesterol. It is responsible for the majority of cholesterol turnover in the human central nervous system. The systematic name of this enzyme class is cholesterol,NADPH:oxygen oxidoreductase (24-hydroxylating).
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice - Nature
-
cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain - PNAS
-
F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy - Journal of Nuclear Medicine
-
Inhibiting Cholesterol 24-Hydroxylase for Epilepsy Treatment - NeurologyLive
-
Brain Pathology | ISN Neuropathology Journal - onlinelibrary.wiley.com
-
Cholesterol byproduct may be therapeutic target for Parkinson’s - Parkinson's News Today
-
Cholesterol Metabolite Implicated in Parkinson’s Disease Pathology - Genetic Engineering and Biotechnology News
-
Takeda Wins Breakthrough Award from Pharmaceutical Society of Japan for Discovery of Soticlestat (TAK-935), a Cholesterol 24-hydroxylase (CH24H) Inhibitor - Takeda Pharmaceuticals
-
Epilepsy fail hands late-stage pipeline blow to Takeda - pharmaphorum
-
Takeda axes failed epilepsy asset after FDA weighs in on data package - Fierce Biotech
-
Study Shows Direct Relationship Between Alzheimer’s Tau Protein and Cholesterol - Neuroscience News
-
AstraZeneca hands off epilepsy programs to Ovid; Amylyx scores priority review for ALS drug - endpoints.news
-
Role of cholesterol in modulating brain hyperexcitability - Wheless - 2025 - Epilepsia - onlinelibrary.wiley.com
-
24(S)-Hydroxycholesterol protects the ex vivo rat retina from injury by elevated hydrostatic pressure - Nature
-
Ovid extends cash runway by selling off slice of royalty rights for Takeda-partnered seizure drug - Fierce Biotech
-
Ovid Therapeutics Inc (NASDAQ: OVID) Share Price, OVID Stock News, OVID Share Price & Updates - Kalkine
-
Neuronal cholesterol metabolism increases dendritic outgrowth and synaptic markers via a concerted action of GGTase-I and Trk - Nature
-
Soticlestat Revived: Perceptive Advisors Bets FDA Rejected Trial Design, Not Drug Itself - Tech Times
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.